CLOPIXOL-ACUPHASE 50MG/ML SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

ZUCLOPENTHIXOL ACETATE

可用日期:

LUNDBECK CANADA INC

ATC代码:

N05AF05

INN（国际名称）:

ZUCLOPENTHIXOL

剂量:

50MG

药物剂型:

SOLUTION

组成:

ZUCLOPENTHIXOL ACETATE 50MG

给药途径:

INTRAMUSCULAR

每包单位数:

5X1ML/5X2ML

处方类型:

Prescription

治疗领域:

THIOXANTHENES

產品總結:

Active ingredient group (AIG) number: 0127601001; AHFS:

授权状态:

APPROVED

授权日期:

1997-01-30

产品特点

_ _
_ _
_Page 1 of 34_
PRODUCT MONOGRAPH
Pr
CLOPIXOL
®
Zuclopenthixol Tablets Lundbeck Std.
(10 mg and 25 mg zuclopenthixol as zuclopenthixol hydrochloride)
Lundbeck standard
Pr
CLOPIXOL-ACUPHASE
®
50 mg/mL Zuclopenthixol Intramuscular Injection
(45.25 mg/mL zuclopenthixol as zuclopenthixol acetate)
Lundbeck standard
Pr
CLOPIXOL
® DEPOT
200 mg/mL Zuclopenthixol Intramuscular Injection
(144.4 mg/mL zuclopenthixol as zuclopenthixol decanoate)
Lundbeck standard
ANTIPSYCHOTIC AGENT
Lundbeck Canada Inc.
1000 De la Gauchetière Street West
Suite 500
Montréal, QC
H3B 4W5
Date of Revision:
08 April 2014
Submission Control No : 171198
_ _
_ _
_Page 2 of 34_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
............................